Incidence and Determinants of Ventilation Tubes in Denmark

PLoS One. 2016 Nov 22;11(11):e0165657. doi: 10.1371/journal.pone.0165657. eCollection 2016.

Abstract

Background and objectives: Many children are treated for recurrent acute otitis media and middle ear effusion with ventilation tubes (VT). The objectives are to describe the incidence of VT in Denmark during 1997-2011 from national register data, furthermore, to analyze the determinants for VT in the Copenhagen Prospective Studies on Asthma in Childhood2010 (COPSAC2010) birth cohort.

Methods: The incidence of VT in all children under 16 years from 1997-2011 were calculated in the Danish national registries. Determinants of VT were studied in the COPSAC2010 birth cohort of 700 children.

Results: Nationwide the prevalence of VT was 24% in children aged 0 to 3 three years, with a significant increase over the study period. For all children 0-15 years, the incidence of VT was 35/1,000. In the VT population, 57% was male and 43% females. In the COPSAC2010 birth cohort, the prevalence of VT during the first 3 years of life was 29%. Determinants of VT were: maternal history of middle ear disease; aHR 2.07, 95% CI [1.45-2.96] and siblings history of middle ear disease; aHR 3.02, [2.11-4.32]. Paternal history of middle ear disease, presence of older siblings in the home and diagnosis of persistent wheeze were significant in the univariate analysis but the association did not persist after adjustment.

Conclusion: The incidence of VT is still increasing in the youngest age group in Denmark, demonstrating the highest incidence recorded in the world. Family history of middle ear disease and older siblings are the main determinants for VT.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Asthma* / epidemiology
  • Asthma* / therapy
  • Child
  • Child, Preschool
  • Denmark / epidemiology
  • Female
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Otitis Media with Effusion* / epidemiology
  • Otitis Media with Effusion* / etiology
  • Registries*
  • Respiration, Artificial* / adverse effects
  • Respiration, Artificial* / instrumentation

Grants and funding

COPSAC is funded by private and public research funds all listed on www.copsac.com. The Lundbeck Foundation (Grant no R16-A1694); The Danish Ministry of Health (Grant no 903516); Danish Council for Strategic Research (Grant no 0603-00280B) and The Capital Region Research Foundation (No grant number) have provided core support for COPSAC. The author has received funding from Oticon Foundation (No grant number) and GN Store Nord Foundation (No grant number). The funding agencies did not have any influence on study design, data collection and analysis, decision to publish or preparation of the manuscript. No pharmaceutical company was involved in the study. The funding agencies did not have any role in design and conduct of the study; collection, management, and interpretation of the data; or preparation, review, or approval of the manuscript. Financial Disclosure: The authors have no financial relationships relevant to this article to disclose.